 |
|
|
| |
Long-term follow-up of patients with chronic HCV infection
&
treated with daclatasvir-based regimens in phase 2 and 3 studies
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-13 Boston, MA
Reddy KR,1Pol S,2ThuluvathPJ,3KumadaH,4Toyota J,5ChayamaK,6Levin J,7LawitzE,8GadanoA,9GhesquiereW,10GerkenG,11BrunettoM,12Peng CY,13Silva M,14StrasserS,15HeoJ,16McPhee F,17Liu Z,18Yang R,17LinaberryM,19NovielloS19
9
1University of Pennsylvania, Philadelphia, PA; 2Hôpital Cochin, Paris, France; 3Mercy Medical Center, Baltimore, MD; 4Toranomon Hospital, Tokyo, Japan; 5Sapporo-Kosei General Hospital, Sapporo, Japan; 6Hiroshima University, Hiroshima, Japan; 7Dean Foundation, Madison, WI; 8Texas Liver Institute and the University of Texas Health Science Center, San Antonio, TX; 9Hospital Italianode Buenos Aires, Buenos Aires, Argentina; 10Vancouver Island Health Authority and University of British Columbia, Victoria, BC; 11University of Duisburg-Essen, Essen, Germany; 12University Hospital, Pisa, Italy; 13School of Medicine, China Medical University, Taichung, Taiwan; 14Hospital UniversitarioAustral, Buenos Aires, Argentina; 15Royal Prince Alfred Hospital, Sydney, Australia; 16College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; 17Bristol-Myers Squibb, Wallingford, CT; 18Bristol-Myers Squibb, Hopewell, NJ; 19Bristol-Myers Squibb, Princeton, NJ
|
| |
|
|
|
|
|
